×
It looks like you're using an obsolete version of internet explorer. Internet explorer is no longer supported by Microsoft since the end of 2015. We invite you to use a newer browser such as Firefox, Google Chrome or Microsoft Edge.
My Player placeholder

Become an Oncostream member and receive full access to its content!

You must be an Oncostream member to access videos without any restrictions. Register for free in one minute and access all services provided by Oncostream.You will also be able to log into Oncostream from your Facebook or twitter account by clicking on login on the top-right corner of Oncostream website.

Registration Login


Worldwide schedules comment Share

Modérateurs : Dr Caroline Bouche, Dr Jean- Marc Classe & Dr Jean-Sébastien Frénel

Intervenants :
Dr Jean-Sébastien Frénel,
Pr Emmanuel Barranger, Centre Antoine Lacassagne, Nice
Pr Roman Rouzier, Institut Curie, Paris
Dr Jean-Marc Classe, Institut de cancerologie de l'ouest, Nantes

Cas n°1 : Cancer du sein Triple négatif apparemment accessible à une chirurgie première…. Est-ce toujours une bonne idée ?
Dr Jean-Sébastien Frénel
 
Cas n°2 : Cancer du sein T1 RH+/HER2- : quelle indication de chirurgie axillaire en fonction du statut N clinique ?
Pr Emmanuel Barranger
 
Cas n°3 : Cancer du sein RH+/ HER2neg de 4 cm : comment pondérer l’indication de traitement systémique ? Place d’une signature génomique.
Pr Roman Rouzier
 
Cas n°4 : Patiente initialement N0, traitée par CNA : quelle chirurgie axillaire après la CNA ?
Dr Jean-Marc Classe
 

 

 
Shooting date : 2024-05-22
Last update : 2024-06-05

Suggestions

Thursday, March 10th 2022 from 07pm to 09pm (GMT+1)
Honolulu : Thursday, March 10th 2022 from 08am to 10am (GMT+1)
San Francisco : Thursday, March 10th 2022 from 10am to 12pm (GMT+1)
New York : Thursday, March 10th 2022 from 01pm to 03pm (GMT+1)
Buenos Aires : Thursday, March 10th 2022 from 03pm to 05pm (GMT+1)
London / Dublin : Thursday, March 10th 2022 from 06pm to 08pm (GMT+1)
Paris / Berlin : Thursday, March 10th 2022 from 07pm to 09pm (GMT+1)
Istanbul : Thursday, March 10th 2022 from 08pm to 10pm (GMT+1)
Moscou / Dubaï : Thursday, March 10th 2022 from 10pm to 12am (GMT+1)
Bangkok : Friday, March 11th 2022 from 01am to 03am (GMT+1)
Shanghai : Friday, March 11th 2022 from 02am to 04am (GMT+1)
Tokyo : Friday, March 11th 2022 from 03am to 05am (GMT+1)
Sydney : Friday, March 11th 2022 from 04am to 06am (GMT+1)
Wellington : Friday, March 11th 2022 from 06am to 08am (GMT+1)

Changement de paradigme dans les cancers du sein triple négatif métastatique - de la théorie à l...

Share
Thursday, October 13th 2022 from 06pm to 07pm (GMT+2)
Honolulu : Thursday, October 13th 2022 from 07am to 08am (GMT+2)
San Francisco : Thursday, October 13th 2022 from 10am to 11am (GMT+2)
New York : Thursday, October 13th 2022 from 01pm to 02pm (GMT+2)
Buenos Aires : Thursday, October 13th 2022 from 02pm to 03pm (GMT+2)
Reykjavik : Thursday, October 13th 2022 from 05pm to 06pm (GMT+2)
London / Dublin : Thursday, October 13th 2022 from 06pm to 07pm (GMT+2)
Paris / Berlin : Thursday, October 13th 2022 from 07pm to 08pm (GMT+2)
Istanbul : Thursday, October 13th 2022 from 08pm to 09pm (GMT+2)
Moscou / Dubaï : Thursday, October 13th 2022 from 09pm to 10pm (GMT+2)
Bangkok : Friday, October 14th 2022 from 12am to 01am (GMT+2)
Shanghai : Friday, October 14th 2022 from 01am to 02am (GMT+2)
Tokyo : Friday, October 14th 2022 from 02am to 03am (GMT+2)
Sydney : Friday, October 14th 2022 from 04am to 05am (GMT+2)
Wellington : Friday, October 14th 2022 from 06am to 07am (GMT+2)

Les inhibiteurs de tyrosine kinase (TKI) et les anticorps conjugués (ADC) dans le cancer du sein mÃ...

Les nouveaux traitements, entre choix et complémentarité

Share
Thursday, May 25th 2023 from 06:30pm to 08pm (GMT+2)
Honolulu : Thursday, May 25th 2023 from 07:30am to 09am (GMT+2)
San Francisco : Thursday, May 25th 2023 from 10:30am to 12pm (GMT+2)
New York : Thursday, May 25th 2023 from 01:30pm to 03pm (GMT+2)
Buenos Aires : Thursday, May 25th 2023 from 02:30pm to 04pm (GMT+2)
Reykjavik : Thursday, May 25th 2023 from 05:30pm to 07pm (GMT+2)
London / Dublin : Thursday, May 25th 2023 from 06:30pm to 08pm (GMT+2)
Paris / Berlin : Thursday, May 25th 2023 from 07:30pm to 09pm (GMT+2)
Istanbul : Thursday, May 25th 2023 from 08:30pm to 10pm (GMT+2)
Moscou / Dubaï : Thursday, May 25th 2023 from 09:30pm to 11pm (GMT+2)
Bangkok : Friday, May 26th 2023 from 12:30am to 02am (GMT+2)
Shanghai : Friday, May 26th 2023 from 01:30am to 03am (GMT+2)
Tokyo : Friday, May 26th 2023 from 02:30am to 04am (GMT+2)
Sydney : Friday, May 26th 2023 from 04:30am to 06am (GMT+2)
Wellington : Friday, May 26th 2023 from 06:30am to 08am (GMT+2)

Cancer du sein RH+ : Quelles optimisations thérapeutiques en 2L métastatique ?

Share
Tuesday, May 14th 2024 from 06pm to 07:30pm (GMT+2)
Honolulu : Tuesday, May 14th 2024 from 07am to 08:30am (GMT+2)
San Francisco : Tuesday, May 14th 2024 from 10am to 11:30am (GMT+2)
New York : Tuesday, May 14th 2024 from 01pm to 02:30pm (GMT+2)
Buenos Aires : Tuesday, May 14th 2024 from 02pm to 03:30pm (GMT+2)
Reykjavik : Tuesday, May 14th 2024 from 05pm to 06:30pm (GMT+2)
London / Dublin : Tuesday, May 14th 2024 from 06pm to 07:30pm (GMT+2)
Paris / Berlin : Tuesday, May 14th 2024 from 07pm to 08:30pm (GMT+2)
Istanbul : Tuesday, May 14th 2024 from 08pm to 09:30pm (GMT+2)
Moscou / Dubaï : Tuesday, May 14th 2024 from 09pm to 10:30pm (GMT+2)
Bangkok : Wednesday, May 15th 2024 from 12am to 01:30am (GMT+2)
Shanghai : Wednesday, May 15th 2024 from 01am to 02:30am (GMT+2)
Tokyo : Wednesday, May 15th 2024 from 02am to 03:30am (GMT+2)
Sydney : Wednesday, May 15th 2024 from 04am to 05:30am (GMT+2)
Wellington : Wednesday, May 15th 2024 from 06am to 07:30am (GMT+2)

Développement thérapeutique dans les cancers du sein triples négatifs métastatiques

Les webinars du réseau FEM-NET

Share
Scroll Up